- NVAX plans to use recombinant nanoparticle vaccine technology for a vaccine candidate, a third party spokeswoman said via email
- NVAX’s Matrix-M platform will be used to bolster potential immune responses
- Meanwhile, not everyone was optimistic, with a B Riley FBR analyst saying there’s “more questions than answers on ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.